Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Raez, L. E. [1 ]
Baca, Y. [2 ]
Nagasaka, M. [3 ]
Nieva, J. [4 ]
Mandani, H. [5 ]
Wanderwalde, A. [6 ]
Borghaei, H. [7 ]
Naban, C.
Langer, C. [8 ,9 ]
Socinsky, M. A. [10 ]
Lopes, G. [11 ]
Khan, H. [12 ]
Wozniak, A. [13 ]
Carracedo, C. [14 ]
Liu, S. [15 ]
机构：
[1] Florida Atlantic Univ, Mem Canc Inst, Miami, FL USA
[2] Caris Life Sci, Irving, TX USA
[3] Univ Calif Irvine, Orange, CA USA
[4] Univ Southern Calif, Los Angeles, CA USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Caris Life Sci, Irvine, CA USA
[7] Fox Chase Canc Ctr, Philadelphia, PA USA
[8] Caris Life Sci, Dallas, TX USA
[9] Univ Penn, Philadelphia, PA USA
[10] Advent Hlth Orlando, Orlando, FL USA
[11] Univ Miami, Miami, FL USA
[12] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[13] UPMC, Hillman Canc Ctr, Philadelphia, PA USA
[14] Florida Atlantic Univ, Mem Canc Inst, Pembroke Pines, FL USA
[15] Georgetown Univ, Washington, DC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR; Next Generation Sequencing; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP16.03-02
引用
收藏
页码：S597 / S597
页数：1
相关论文
共 50 条
  • [1] Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)
    Raez, Luis E.
    Baca, Yasmine
    Carracedo, Carlos
    Vanderwalde, Ari
    Nabhan, Chadi
    Nagasaka, Misako
    Nieva, Jorge
    Mandani, Hirva
    Borghaei, Hossein
    Socinski, Mark
    Khan, Hina
    Wozniak, Antoinette
    Lopes, Gilberto
    Liu, Stephen
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S3 - S3
  • [2] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    [J]. LUNG CANCER, 2021, 156 : S40 - S40
  • [3] RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC)
    Fan, Ni
    Zou, Yiyu
    Halmos, Balazs
    Perez-Soler, Roman
    Cheng, Haiying
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [4] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    [J]. ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [5] Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)
    Schmid, Sabine
    Gautschi, Oliver
    Rothschild, Sacha
    Mauti, Laetitia
    Mark, Michael
    Froesch, Patrizia
    Fruh, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1505 - S1505
  • [6] Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only
    Vila, L.
    Pardo, N.
    Cuadra, J. L.
    Capdevila, L.
    Moran, T.
    Carcereny, E.
    Queralt, C.
    De Aguirre, I.
    Taron, M.
    Rosell, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S822 - S822
  • [7] Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Pao, William
    Miller, Vincent A.
    Kris, Mark G.
    Varmus, Harold E.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 4 - 4
  • [8] Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitor (TKI)
    Sun, Jong-Mu
    Park, Min Jae
    Yi, Jun Ho
    Kong, Jeehyun
    Kim, Jung-A
    Lee, Soohyeon
    Yun, Lin A.
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S716 - S716
  • [9] Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only.
    Capdevila, Laia
    Carcereny, Enric
    de Aguirre, Itziar
    Cros, Sara
    Queralt, Cristina
    Moran, Teresa
    Buges, Cristina
    Mijangos, Erika
    Pardo, Nuria
    Rosell, Rafael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
12345